tapebrief
DGX · Q2 2025

DGX · Q3 2025 Earnings

Bullish

Quest Diagnostics

Reported October 21, 2025

30-second summary

Quest delivered Q3 revenue of $2.82B (+13.1% YoY) and adjusted EPS of $2.60, with management raising FY2025 revenue, adjusted EPS, organic growth, and operating cash flow guidance — the second consecutive mid-year raise. The headline shift: organic revenue growth assumption stepped up 100–150bps to 4.5–5.0%, CoLab solutions was explicitly quantified at ~$1B annual run-rate once fully scaled across Corewell's 21 hospital labs in 2026, and operating cash flow guidance jumped $250M to ~$1.8B (helped by ~$146–176M of one-time tax and CARES benefits that need to be backed out for 2026 modeling). The hidden caveat: GAAP EPS guidance was narrowed and the midpoint trimmed by $0.04 despite the revenue raise, pointing to tax or discrete-item drag below the operating line.

Headline numbers

EPS

Q3 FY2025

$2.60

Revenue

Q3 FY2025

$2.82B

+13.1% YoY

Free cash flow

Q3 FY2025

$0.42B

Operating margin

Q3 FY2025

13.7%

Key financials

Q3 FY2025
MetricQ3 FY2025YoYQ2 FY2025QoQ
Revenue$2.82B+13.1%$2.76B+2.0%
EPS$2.60—$2.62-0.8%
Operating margin13.7%—15.9%-220bps
Free cash flow$0.42B—$0.32B+31.3%

Guidance

Company raised full-year revenue and non-GAAP EPS guidance with a significant +100-150bps organic growth acceleration, offset by slightly narrowed GAAP EPS range suggesting tax or discrete item headwinds.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Changes to prior guidance

MetricPeriodPrior guideNew guideΔResult
Revenue
FY2025
$10.80B to $10.92B$10.96B to $11.00B+$0.16B to +$0.20B at midpointRaised
Diluted EPS (GAAP)
FY2025
$8.60 to $8.80$8.58 to $8.66-$0.02 to -$0.14 at range; midpoint -$0.04Lowered
Adjusted Diluted EPS
FY2025
$9.63 to $9.83$9.76 to $9.84+$0.13 to +$0.21 at range; midpoint +$0.09Raised
Organic Revenue Growth
FY2025
3.5% to 4.0%4.5% to 5.0%+1.0 to +1.5 percentage pointsRaised
Cash Provided by Operations
FY2025
Approximately $1.55BApproximately $1.80B+$0.25B (+16%)Raised

Reaffirmed unchanged this quarter: Capital Expenditures (Approximately $500M)

Segment KPIs

Q3 FY2025
SegmentQ3 FY2025YoY
Diagnostic Information Services$2.755B+13.5%

Other KPIs

Q3 FY2025
SegmentQ3 FY2025
Requisition Volume Growth12.5%
Organic Requisition Volume Growth3.9%
Revenue per Requisition Growth0.8%
Operating Margin (GAAP)13.7%
Operating Margin (Adjusted)16.3%
Operating Cash Flow (YTD)$1.421B
Co-Lab Solutions Annual Revenue Target$1.0B

Management tone

Customer optimization hangover → AI experiments → Consumer channel scaling → CoLab and AD Detect quantified as material engines.

Hospital channel framing shifted from defensive to monetized. Last quarter management positioned hospital wins as opportunistic share takes from in-house labs under financial pressure; this quarter they put a number on it. The anchor quote: "Once we fully scale across Corwell's 21 hospital labs next year, we expect annual revenues from CoLab solutions to be approximately $1 billion." Quantifying a partnership model at ~9% of current run-rate revenue is not a soft signal — management is telling investors to model this as a discrete growth engine.

Alzheimer's testing crossed from emerging opportunity to inflecting product. Two quarters ago AD Detect was one bullet in advanced diagnostics; last quarter management cited strong growth alongside cardiometabolic; this quarter demand "more than doubled" in a single quarter with newly published clinical evidence. The shift in vocabulary from "growth" to "accelerated" and "doubled" matters when management has historically reserved such language for established franchises.

Consumer channel moved from milestone-counting to embedded-infrastructure positioning. Last quarter's tone leaned on the cumulative 1M order milestone; this quarter management reframed Quest as "the preferred lab engine of consumer health companies" with named integrations (Whoop, Aura). Q&A disclosed consumer business growth of 30–40% YTD with no bad debt. The structural framing — Quest as embedded infrastructure rather than retail counterparty — implies durability that pure DTC growth metrics don't capture.

PAMA shifted from policy risk to existential urgency. Last quarter PAMA was "before three committees" with a delay as fallback; this quarter management explicitly said: "If Congress does not reform or delay PAMA this year, American labs will be forced to absorb significant payment cuts next year, threatening the ability of American seniors to access critical lab testing." Q&A confirmed the $100M exposure is unchanged and that the Results Act (full reform) is now "difficult to pass," with delay the higher-probability outcome. The tonal escalation suggests management views resolution timing as binary and imminent.

Project Nova matured from investment story to multi-year operating transformation with a partner name. Epic is now the disclosed technology partner, MyQuest will migrate to MyChart, and the implementation timeline is 5–7 years with $250–310M of total spend (mix of OPEX and CAPEX). The granularity reframes Nova from a margin headwind into a defined capital program with end states investors can hold management to.

Recurring themes management leaned on this quarter:

Advanced diagnostics portfolio acceleration across five clinical areasConsumer channel momentum and embedded health brand partnershipsCoLab solutions scaling into hospital systems with material revenue potentialAI and automation deployment for productivity gains via Invigorate programProject Nova order-to-cash transformation with Epic as technology partnerM&A strategy focused on accretive hospital outreach and independent labs

Risks management surfaced:

PAMA reimbursement cuts threatening lab access if Congress does not reformWage increases and higher than expected employee health care costs pressuring marginsIntegration execution risk on multi-year Project Nova transformationDialysis center service scaling completion timing (expected early 2026)Prospective M&A contributions not assumed in updated guidance

Q&A highlights

Patrick Donnelly · Citi

Asked about elevated utilization backdrop and expectations into year-end; also queried PAMA expectations, probability of passage, and potential offsets for 2026.

Management reported raw rec volume up 3.9% organically and rep per rec up 3%, driven by network gains with Elevance and Sentara, strong mix in autoimmune and cardio testing, and consumer channel growth (30-40% YTD). On PAMA, stated Results Act is difficult to pass but PAMA delay has higher probability; quantified $100M impact if PAMA returns with partial offsets planned; expects Q4 utilization to continue at Q3 levels.

Raw rec volume organic growth: 3.9%Organic rep per rec growth: 3%Consumer business growth: 30-40% YTDPAMA impact if enacted: $100 million

Elizabeth Anderson · Evercore ISI

Asked about 4Q margin drivers given strong expansion YTD and Project NOVA expense ramp; requested breakdown of puts and takes.

Management noted Q3 operating margins of 16.3% with 60 bps YTD expansion. Identified group health expenses as ~40-50 bps headwind in Q3 expected to continue in Q4. Flagged NOVA investment ramp in Q4 due to Epic signing timing. Highlighted typical pre-COVID seasonality of 50-100 bps margin decline Q3 to Q4. Credited Invigorate productivity program as ongoing margin driver.

Q3 operating margins: 16.3%YTD operating margin expansion: 60 basis pointsGroup health expense headwind: 40-50 basis points in Q3Typical Q3-Q4 seasonal decline: 50-100 basis points

Kevin Caliendo · UBS

Asked about 2026 headwinds and tailwinds beyond PAMA, including impact of incremental Corwell investment spend and alignment with long-range plan.

Management confirmed LRP assumptions remain intact (mid-single-digit revenue growth including 1-2% from M&A, high single-digit EPS growth, margin expansion). Identified tailwinds: utilization, test-per-rec, mix improvements, Fresenius dialysis volumes, Corwell co-lab expansion (rolling across all 21 hospitals in 2026), consumer health momentum. Headwinds: PAMA, ACA subsidy expiration, hospital reimbursement pressure. Stated investment spend including NOVA is consistent with March guidance and pace is controllable based on macro conditions.

LRP revenue growth: mid-single-digit including 1-2% from M&ALRP EPS growth: high single-digitFresenius dialysis volume contribution: >200,000 patients across 3,100+ centersCorwell rollout: all 21 hospitals in 2026

Jack Mann · Nefron Research

Asked about cash flow conversion strength and one-timer items to isolate baseline for 2026 modeling.

Management raised operating cash flow guidance to $1.8B (up $250M). Identified one-timers: CARES Act payment ($46M), tax legislation benefits ($100-130M) from accelerated bonus depreciation and R&D expensing under One Big Beautiful Bill Act. Highlighted consumer channel cash generation advantage (payment at order, no patient concessions/bad debt). Noted visibility into timing of receipts and collections driving strength.

Operating cash flow guidance: $1.8 billionCARES Act payment (non-recurring): $46 millionTax benefit one-timers: $100-130 millionConsumer channel payment: collected at time of order with no bad debt

Erin Wright · Morgan Stanley

Asked to break out impact of One Big Beautiful Bill vs. ACA subsidy expiration (noted as 50-60 bps in 10-Q); also requested details on Epic partnership genesis and timing.

Management stated majority of 50-60 bps impact is from ACA subsidy expiration (~40-45 bps), with remainder from Medicaid ramp (minimal impact through 2028). On Epic: foundational element is conversion of laboratory information systems to Epic's Beaker LIS; will start implementations in esoteric sites then roll out regionally over several years. MyQuest will upgrade to MyChart, enabling patient integration of Quest data with health system records. Five-to-seven year implementation timeline with methodical pacing due to internal/customer change management.

ACA subsidy expiration impact: 40-45 basis points (of 50-60 bps total)Medicaid impact through 2028: minimalEpic Beaker LIS implementation: starting 2026, rolling out regionally over several yearsEpic implementation timeline: 5-7 years

Answers to last quarter's watch list

Organic revenue growth holding at/above 5.2% — Management did not disclose a consolidated organic revenue growth rate for Q3 in this print. Organic requisition volume of +3.9% accelerated from +2.1% in Q2, and the FY organic guide was raised to 4.5–5.0% from 3.5–4.0%, implying continued underlying strength.
Continue monitoring
Organic requisition growth above 2.1% — Organic requisition volume came in at +3.9%, well above the Q2 mark and confirming the inflection is widening, not narrowing. Q&A confirmed organic rev-per-rec also held at ~3%.
Resolved positively
PAMA resolution path — Unresolved and now more urgent. Management explicitly framed Q4 as the deadline for congressional action, said full reform via the Results Act is unlikely to pass, and identified delay as the higher-probability outcome. The $100M 2026 exposure stands with limited offsets.
Continue monitoring
H2 operating margin trajectory — Q3 adjusted operating margin of 16.3% delivered 60bps of YTD expansion, and FY margin expansion vs. prior year was reaffirmed. However, management flagged 50–100bps of typical Q3-to-Q4 seasonal decline plus 40–50bps of group health headwind and Nova investment ramp landing in Q4. The FY math still works but Q4 will be the cleanest test.
Continue monitoring
LifeLabs integration milestones — No specific cost synergy or run-rate margin disclosure on LifeLabs this quarter; the integration narrative was subsumed by the broader Corewell/CoLab story.
Not resolved
DTC scale disclosures — Quest disclosed consumer business growth of 30–40% YTD in Q&A and named Whoop and Aura as embedded partners but did not begin formal periodic disclosure of DTC revenue or order count. Management did highlight the consumer channel's cash flow advantage (payment at order, no bad debt).
Continue monitoring

What to watch into next quarter

CoLab revenue trajectory toward the $1B target: with Corewell rolling across all 21 hospitals in 2026, watch for any Q4 disclosure of CoLab revenue contribution or implementation pace milestones that confirm or stretch the timeline.

Q4 adjusted operating margin holding above 15.3%: management telegraphed 50–100bps of seasonal step-down from Q3's 16.3% plus group-health and Nova drag. Anything below that range puts FY margin expansion at risk.

PAMA outcome by year-end: binary catalyst. A delay preserves the $100M exposure into 2026 modeling; full reform removes it; inaction crystallizes it. Resolution is expected before Congress adjourns.

Initial FY2026 guidance shape: watch whether the reported organic growth rate guide starts with a 4-handle (consistent with this year's raised 4.5–5.0% range) or steps down to the 3% range the LRP could accommodate.

2026 OCF baseline after stripping $146–176M of one-timers: the raised $1.8B FY2025 OCF includes $46M CARES Act and $100–130M tax benefits that don't repeat. A clean 2026 starting point is closer to $1.62–$1.65B before growth; watch how management frames it.

AD Detect disclosure cadence: with Q3 demand more than doubling and clinical evidence accumulating, watch whether management begins formal periodic disclosure of advanced diagnostics or Alzheimer's testing revenue.

Sources

  1. Quest Diagnostics Q3 FY2025 press release (SEC filing): https://www.sec.gov/Archives/edgar/data/1022079/000102207925000219/dgx093020258-kex991.htm
  2. Quest Diagnostics Q3 FY2025 earnings call transcript (prepared remarks and Q&A).

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.